A Phase III Study of Adjuvant Ganglioside Vaccination GM2-KLH/QS-21 Therapy vs. High-Dose Interferon Alfa-2b (IntronA) for High-Risk Melanoma (T4 > 4 mm Primary or Regional Lymph Node Metastasis)

K
Kathy Miller, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this study was to assess at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

Description

The purpose of this study was to assess at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    melanoma
  • Age: - 100 Years
  • Gender: All
Updated on 20 Nov 2022. Study ID: 1609341481

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center